Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Other Non-Current Liabilities (2020 - 2024)

Historic Other Non-Current Liabilities for Cellebrite DI (CLBT) over the last 6 years, with Q3 2025 value amounting to $7.5 million.

  • Cellebrite DI's Other Non-Current Liabilities fell 471.96% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year decrease of 471.96%. This contributed to the annual value of $7.0 million for FY2024, which is 8715.01% down from last year.
  • Cellebrite DI's Other Non-Current Liabilities amounted to $7.5 million in Q3 2025, which was down 471.96% from $6.9 million recorded in Q2 2025.
  • In the past 5 years, Cellebrite DI's Other Non-Current Liabilities ranged from a high of $93.5 million in Q2 2024 and a low of $6.5 million during Q1 2022
  • Its 5-year average for Other Non-Current Liabilities is $30.1 million, with a median of $20.0 million in 2022.
  • Per our database at Business Quant, Cellebrite DI's Other Non-Current Liabilities skyrocketed by 81225.97% in 2021 and then plummeted by 9267.24% in 2025.
  • Over the past 5 years, Cellebrite DI's Other Non-Current Liabilities (Quarter) stood at $56.5 million in 2021, then tumbled by 64.56% to $20.0 million in 2022, then surged by 170.38% to $54.1 million in 2023, then plummeted by 87.15% to $7.0 million in 2024, then increased by 8.0% to $7.5 million in 2025.
  • Its Other Non-Current Liabilities stands at $7.5 million for Q3 2025, versus $6.9 million for Q2 2025 and $6.6 million for Q1 2025.